肝细胞癌患者跨肿瘤分期和治疗过程中的循环肿瘤DNA
该研究分析了173例肝细胞癌患者的772份血浆样本,检测cfDNA浓度及TERT启动子、CTNNB1、TP53、PIK3CA和NFE2L2突变。活动性肝细胞癌患者ctDNA突变率为40.2%,高于非活动性患者的14.6%和对照组的1.8%(p<0.001)。ctDNA突变率随肿瘤分期进展而升高(p<0.001),治疗前ctDNA突变与经皮消融后死亡和复发风险升高相关。
要点
- 活动性肝细胞癌患者ctDNA突变率为40.2%,非活动性为14.6%,对照组为1.8%(p<0.001)。
- 经皮消融前ctDNA突变的存在和数量与死亡风险(p=0.001)和复发风险(p<0.001)升高相关。
- 阿替利珠单抗-贝伐珠单抗治疗中ctDNA突变持续存在与影像学进展相关(63.6% vs 消失者36.4%,p=0.019)。
核心结论
- ctDNA提供反映肿瘤生物学的动态信息,是一种有助于指导肝细胞癌临床管理的非侵入性工具。
研究设计与样本
- 研究分析了173例肝细胞癌患者的772份血浆,包括诊断或治疗时502份、局部区域治疗后24小时154份、随访期间116份。
- 对照组为56份无肝细胞癌的慢性肝病患者的血浆,所有样本检测cfDNA浓度及TERT启动子、CTNNB1、TP53、PIK3CA和NFE2L2突变。
- 结果与232份对应的肿瘤样本进行比较。
主要发现
- 活动性肝细胞癌患者中40.2%的ctDNA存在突变,非活动性肝细胞癌患者为14.6%,对照组为1.8%(p<0.001)。
- 活动性肝细胞癌中,TERT启动子突变占27.5%,TP53占21.3%,CTNNB1占13.1%,PIK3CA占0.4%,NFE2L2占0.2%,多数与对应肿瘤样本中识别的突变相似。
- ctDNA突变率随晚期肿瘤分期升高(p<0.001)。
- 在103例接受经皮消融的患者中,治疗前ctDNA中突变的存在和数量与较高的死亡风险(p=0.001)和复发风险(p<0.001)相关。
- 局部区域治疗后24小时cfDNA浓度和可检测的突变增加;在53例接受全身治疗的患者的356份血浆中,基线时60.4%的病例检测到突变。
临床怎么用
- 原文结论认为ctDNA提供反映肿瘤生物学的动态信息,是一种有助于指导肝细胞癌临床管理的非侵入性工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Circulating tumour DNA (ctDNA) is a promising non-invasive biomarker in cancer. We aim to assess the dynamic of ctDNA in patients with hepatocellular carcinoma (HCC). DESIGN: We analysed 772 plasmas from 173 patients with HCC collected at the time of diagnosis or treatment (n=502), 24 hours after locoregional treatment (n=154) and during follow-up (n=116). For controls, 56 plasmas from patients with chronic liver disease without HCC were analysed. All samples were analysed for cell free DNA (cfDNA) concentration, and for mutations in TERT promoter, CTNNB1, TP53, PIK3CA and NFE2L2 by sequencing and droplet-based digital PCR. Results were compared with 232 corresponding tumour samples. RESULTS: In patients with active HCC, 40.2% of the ctDNA was mutated vs 14.6% in patients with inactive HCC and 1.8% in controls (p<0.001). In active HCC, we identified 27.5% of mutations in TERT promoter, 21.3% in TP53, 13.1% in CTNNB1, 0.4% in PIK3CA and 0.2% in NFE2L2, most of the times similar to those identified in the corresponding tumour. CtDNA mutation rate increased with advanced tumour stages (p<0.001). In 103 patients treated by percutaneous ablation, the presence and number of mutations in the ctDNA before treatment were associated with higher risk of death (p=0.001) and recurrence (p<0.001). Interestingly, cfDNA concentration and detectable mutations increased 24 hours after a locoregional treatment. Among 356 plasmas collected in 53 patients treated by systemic treatments, we detected mutations at baseline in 60.4% of the cases. In patients treated by atezolizumab-bevacizumab, persistence of mutation in ctDNA was associated with radiological progression (63.6% vs 36.4% for disappearance, p=0.019). In two patients progressing under systemic treatments, we detected the occurrence of mutations in CTNNB1 in the plasma that was subclonal in the tumour for one patient and not detectable in the tumour for the other one. CONCLUSION: ctDNA offers dynamic information reflecting tumour biology. It represents a non-invasive tool useful to guide HCC clinical management.
引用
- Campani C, Imbeaud S, Couchy G, et al. Circulating tumour DNA in patients with hepatocellular carcinoma across tumour stages and treatments. Gut. 2024. PMID: 39054058. doi:10.1136/gutjnl-2024-331956
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。